
Carlsmed rose 40.9% from $12.31 to $17.35, ahead of the S&P 500's +11.2%. Its worst day was Dec 4 (−15.2%), and its low came Apr 29 at $8.83.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Carlsmed shares fell 15.2%, while the S&P 500 rose 0.1%.
−15.2%, the year's worst day · S&P 500 +0.1%
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024CARLSBAD, Calif., Jan.
Story events cover the past 12 months · Times ET
+13.8% · S&P 500 +0.2%
EPS of $-0.32 beat the $-0.43 estimate on $15.2M revenue (est. $14.9M); FY revenue guidance of $70.0M–$75.0M against the $69.5M consensus.
+15.9% · S&P 500 −0.6%
EPS of $-0.32 beat the $-0.40 estimate on $16.1M revenue (est. $14.9M); FY revenue guidance of $72.0M–$77.0M against the $72.5M consensus.
+10.3% · S&P 500 +1.4%
Carlsmed shares rose 12.8%, while the S&P 500 fell 0.1%.
+12.8% · S&P 500 −0.1%
EPS of $-0.39 missed the $-0.38 estimate on $18.9M revenue (est. $18.1M); FY revenue guidance of $74.0M–$78.0M against the $75.0M consensus.
+1.0% · S&P 500 −0.2%
EPS of $-0.34 beat the $-0.39 estimate on $21.6M revenue (est. $19.2M); FY revenue guidance of $78.0M–$80.0M against the $76.7M consensus.
+26.4%, the year's best day · S&P 500 +1.3%
Where it ended: a close of $17.35 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-0.36, revenue est. $23.9M).
Nothing in the past 12 months.
All CARL dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CARL and SPY from Benzinga historical bars. Not investment advice.